Completed PHASE1 INTERVENTIONAL NCT00298701

Tolerability of Grazax-R in Children

A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of GRAZAX-R in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)

Sponsor: ALK-Abelló A/S

Conditions Allergy

Interventions ALK Grass tablet

Updated 5 times since 2017 Last updated: May 3, 2006 Started: Feb 28, 2006 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Allergy and is currently completed. ALK-Abelló A/S leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ALK-Abelló A/S

Data source: ALK-Abelló A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamburg, Germany